Clinical Evaluation of Imipenem/Cilastatin Sodium and Fosfomycin as Second-Line Combination Chemotherapy in Severe Infections Associated with Hematologic Disorders

Shoichiro Tsuda, Yuko Kuzuyama, Hiroyuki Nakai, Taku Seriu, Teruyuki Takashima, Sinji Tanaka, Shigeo Horiike, Masafumi Taniwaki, Shinichi Misawa, Kei Kashima, Hitoshi Nakagawa, Hiroshi Fujii, Tetsuro Nakai, Yasuo Okawara, Hitosi Imanishi, Shohei Yokota, Hikari Nishigaki, Kazuhiro Nishida

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Imipenem/cilastatin sodium (IPM/CS) which is a broad-spectrum agent against both Gram-positive and -negative bacteria was used in combination with fosfomycin (FOM) as a second-line chemotherapy for severe infections associated with hematologic disorders. FOM was partnered with IPM because FOM may enhance the bacteriocidal effects of IPM when given as pretreatment to IPM/CS therapy.

Original languageEnglish (US)
Pages (from-to)171-183
Number of pages13
JournalJapanese Journal of Antibiotics
Volume46
Issue number2
DOIs
StatePublished - 1993

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Clinical Evaluation of Imipenem/Cilastatin Sodium and Fosfomycin as Second-Line Combination Chemotherapy in Severe Infections Associated with Hematologic Disorders'. Together they form a unique fingerprint.

  • Cite this

    Tsuda, S., Kuzuyama, Y., Nakai, H., Seriu, T., Takashima, T., Tanaka, S., Horiike, S., Taniwaki, M., Misawa, S., Kashima, K., Nakagawa, H., Fujii, H., Nakai, T., Okawara, Y., Imanishi, H., Yokota, S., Nishigaki, H., & Nishida, K. (1993). Clinical Evaluation of Imipenem/Cilastatin Sodium and Fosfomycin as Second-Line Combination Chemotherapy in Severe Infections Associated with Hematologic Disorders. Japanese Journal of Antibiotics, 46(2), 171-183. https://doi.org/10.11553/antibiotics1968b.46.171